LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 38

Suchoptionen

Artikel: Olmesartan induced weight loss and small vessel vasculitis.

Vanbelleghem, E / Taelman, T / Werbrouck, J / Libbrecht, L / D'Heygere, F

2023 Band 86, Heft 1, Seite(n) 102–104

Mesh-Begriff(e)	Humans ; Imidazoles/adverse effects ; Tetrazoles/adverse effects ; Weight Loss ; Vasculitis
Chemische Substanzen	olmesartan (8W1IQP3U10) ; Imidazoles ; Tetrazoles
Sprache	Englisch
Erscheinungsdatum	2023-02-24
Erscheinungsland	Belgium
Dokumenttyp	Case Reports
ZDB-ID	127060-6
ISSN	1784-3227 ; 0001-5644
ISSN	1784-3227 ; 0001-5644
DOI	10.51821/86.1.10415
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ui V Zs.37: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: A case of Clindamycin-induced aphagia.

Callens, R / Van Eygen, S / D'Heygere, F

Acta gastro-enterologica Belgica

2019 Band 81, Heft 4, Seite(n) 540–541

Mesh-Begriff(e)	Aged, 80 and over ; Clindamycin/administration & dosage ; Clindamycin/adverse effects ; Deglutition Disorders/chemically induced ; Feeding Behavior ; Humans ; Male
Chemische Substanzen	Clindamycin (3U02EL437C)
Sprache	Englisch
Erscheinungsdatum	2019-01-14
Erscheinungsland	Belgium
Dokumenttyp	Case Reports ; Letter
ZDB-ID	127060-6
ISSN	1784-3227 ; 0001-5644
ISSN	1784-3227 ; 0001-5644
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ui V Zs.37: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.

Alsoud, Dahham / Sabino, João / Franchimont, Denis / Cremer, Anneline / Busschaert, Julie / D'Heygere, François / Bossuyt, Peter / Vijverman, Anne / Vermeire, Séverine / Ferrante, Marc

Inflammatory bowel diseases

2024

Abstract: Background: As real-world data on risankizumab in patients with moderate to severe Crohn's disease (CD) are scarce, we evaluated its effectiveness and safety in multirefractory Belgian patients.: Methods: Data from consecutive adult CD patients who ... ...

Abstract	Background: As real-world data on risankizumab in patients with moderate to severe Crohn's disease (CD) are scarce, we evaluated its effectiveness and safety in multirefractory Belgian patients. Methods: Data from consecutive adult CD patients who started risankizumab before April 2023 were retrospectively collected at 6 Belgian centers. Clinical remission and response were defined using the 2-component patient-reported outcome. Endoscopic response was defined as a decrease in baseline Simple Endoscopic Score with ≥50%. Both effectiveness end points were evaluated at week 24 and/or 52, while surgery-free survival and safety were assessed throughout follow-up. Results: A total of 69 patients (56.5% female, median age 37.2 years, 85.5% exposed to ≥4 different advanced therapies and 98.6% to ustekinumab, 14 with an ostomy) were included. At week 24, 61.8% (34 of 55) and 18.2% (10 of 55) of patients without an ostomy achieved steroid-free clinical response and remission, respectively. At week 52, these numbers were 58.2% (32 of 55) and 27.3% (15 of 55), respectively. Endoscopic data were available in 32 patients, of whom 50.0% (16 of 32) reached endoscopic response within the first 52 weeks. Results in patients with an ostomy were similar (steroid-free clinical response and remission, 42.9% and 14.3%, respectively). During a median follow-up of 68.3 weeks, 18.8% (13 of 69) of patients discontinued risankizumab, and 20.3% (14 of 69) of patients underwent CD-related intestinal resections. The estimated surgery-free survival at week 52 was 75.2%. No new safety issues were observed. Conclusions: In this real-world cohort of multirefractory CD patients, risankizumab was effective in inducing both clinical remission and endoscopic response. Risankizumab was well tolerated with no safety issues.
Sprache	Englisch
Erscheinungsdatum	2024-01-12
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	1340971-2
ISSN	1536-4844 ; 1078-0998
ISSN (online)	1536-4844
ISSN	1078-0998
DOI	10.1093/ibd/izad315
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 4530: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Mimicry of an acute pseudocyst by a gastrointestinal duplication cyst in a 14-year-old boy.

Billiet, Thomas / Elewaut, Ann / d'Heygere, François / de Hertogh, Gert / Aerts, Raymond / Verslype, Chris / Laleman, Wim

Endoscopy

2021 Band 54, Heft 6, Seite(n) E271–E272

Mesh-Begriff(e)	Adolescent ; Cysts/complications ; Cysts/diagnostic imaging ; Cysts/surgery ; Digestive System Abnormalities ; Humans ; Intestinal Diseases ; Male ; Pancreatic Pseudocyst/complications ; Pancreatic Pseudocyst/diagnostic imaging ; Pancreatic Pseudocyst/surgery
Sprache	Englisch
Erscheinungsdatum	2021-06-18
Erscheinungsland	Germany
Dokumenttyp	Case Reports ; Journal Article
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-1508-5546
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 669: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Hefte anzeigen

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: Mimicry of an acute pseudocyst by a gastrointestinal duplication cyst in a 14-year-old boy

Billiet, Thomas / Elewaut, Ann / d’Heygere, François / de Hertogh, Gert / Aerts, Raymond / Verslype, Chris / Laleman, Wim

Endoscopy

2021 Band 54, Heft 06, Seite(n) E271–E272

Sprache	Englisch
Erscheinungsdatum	2021-06-18
Verlag	Georg Thieme Verlag KG
Erscheinungsort	Stuttgart ; New York
Dokumenttyp	Artikel
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-1508-5546
Datenquelle	Thieme Verlag

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 669: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Hefte anzeigen

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Phyletic distribution and conservation of the bacterial transcription termination factor Rho.

D'Heygère, François / Rabhi, Makhlouf / Boudvillain, Marc

Microbiology (Reading, England)

2013 Band 159, Heft Pt 7, Seite(n) 1423–1436

Abstract: Transcription termination factor Rho is a ring-shaped, ATP-dependent molecular motor that targets hundreds of transcription units in Escherichia coli. Interest in Rho was renewed recently on the realization that this essential factor is involved in ... ...

Abstract	Transcription termination factor Rho is a ring-shaped, ATP-dependent molecular motor that targets hundreds of transcription units in Escherichia coli. Interest in Rho was renewed recently on the realization that this essential factor is involved in multiple interactions and cellular processes that protect the E. coli genome and regulate its expression on a global scale. Yet it is currently unknown if (and how) Rho-dependent mechanisms are conserved throughout the bacterial kingdom. Here, we mined public databases to assess the distribution, expression and structural conservation of Rho across bacterial phyla. We found that rho is present in more than 90 % of sequenced bacterial genomes, although Cyanobacteria, Mollicutes and a fraction of Firmicutes are totally devoid of rho. Genomes lacking rho tend to be small and AT-rich and often belong to species with parasitic/symbiotic lifestyles (such as Mollicutes). By contrast, large GC-rich genomes, such as those of Actinobacteria, often contain rho duplicates and/or encode Rho proteins that bear insertion domains of unknown function(s). Notwithstanding, most Rho sequences across taxa contain canonical RNA-binding and ATP hydrolysis signature motifs, a feature suggestive of largely conserved mechanism(s) of action. Mutations that impair binding of bicyclomycin are present in ~5 % of rho sequences, implying that species from diverse ecosystems have developed resistance against this natural antibiotic. Altogether, these findings assert that Rho function is widespread among bacteria and suggest that it plays a particularly relevant role in the expression of complex genomes and/or bacterial adaptation to changing environments.
Mesh-Begriff(e)	Bacteria/classification ; Bacteria/genetics ; Bacteria/metabolism ; Conserved Sequence/genetics ; Databases, Genetic ; Escherichia coli/genetics ; Escherichia coli/metabolism ; Escherichia coli Proteins/genetics ; Escherichia coli Proteins/metabolism ; Genome, Bacterial ; Phylogeny ; Rho Factor/genetics ; Sequence Alignment ; Species Specificity ; Transcription, Genetic
Chemische Substanzen	Escherichia coli Proteins ; Rho Factor
Sprache	Englisch
Erscheinungsdatum	2013-05-23
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1180712-x
ISSN	1465-2080 ; 1350-0872
ISSN (online)	1465-2080
ISSN	1350-0872
DOI	10.1099/mic.0.067462-0
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ud II Zs.140: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: ATP-dependent motor activity of the transcription termination factor Rho from Mycobacterium tuberculosis.

D'Heygère, François / Schwartz, Annie / Coste, Franck / Castaing, Bertrand / Boudvillain, Marc

Nucleic acids research

2015 Band 43, Heft 12, Seite(n) 6099–6111

Abstract: The bacterial transcription termination factor Rho-a ring-shaped molecular motor displaying directional, ATP-dependent RNA helicase/translocase activity-is an interesting therapeutic target. Recently, Rho from Mycobacterium tuberculosis (MtbRho) has been ...

Abstract	The bacterial transcription termination factor Rho-a ring-shaped molecular motor displaying directional, ATP-dependent RNA helicase/translocase activity-is an interesting therapeutic target. Recently, Rho from Mycobacterium tuberculosis (MtbRho) has been proposed to operate by a mechanism uncoupled from molecular motor action, suggesting that the manner used by Rho to dissociate transcriptional complexes is not conserved throughout the bacterial kingdom. Here, however, we demonstrate that MtbRho is a bona fide molecular motor and directional helicase which requires a catalytic site competent for ATP hydrolysis to disrupt RNA duplexes or transcription elongation complexes. Moreover, we show that idiosyncratic features of the MtbRho enzyme are conferred by a large, hydrophilic insertion in its N-terminal 'RNA binding' domain and by a non-canonical R-loop residue in its C-terminal 'motor' domain. We also show that the 'motor' domain of MtbRho has a low apparent affinity for the Rho inhibitor bicyclomycin, thereby contributing to explain why M. tuberculosis is resistant to this drug. Overall, our findings support that, in spite of adjustments of the Rho motor to specific traits of its hosting bacterium, the basic principles of Rho action are conserved across species and could thus constitute pertinent screening criteria in high-throughput searches of new Rho inhibitors.
Mesh-Begriff(e)	Adenosine Triphosphatases/metabolism ; Adenosine Triphosphate/metabolism ; Allosteric Regulation ; Bacterial Proteins/chemistry ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Mutant Proteins/metabolism ; Mycobacterium tuberculosis/enzymology ; RNA Helicases/chemistry ; RNA Helicases/genetics ; RNA Helicases/metabolism ; RNA, Double-Stranded/metabolism ; Rho Factor/chemistry ; Rho Factor/genetics ; Rho Factor/metabolism ; Transcription Termination, Genetic
Chemische Substanzen	Bacterial Proteins ; Mutant Proteins ; RNA, Double-Stranded ; Rho Factor ; Adenosine Triphosphate (8L70Q75FXE) ; Adenosine Triphosphatases (EC 3.6.1.-) ; RNA Helicases (EC 3.6.4.13)
Sprache	Englisch
Erscheinungsdatum	2015-07-13
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	186809-3
ISSN	1362-4962 ; 1362-4954 ; 0301-5610 ; 0305-1048
ISSN (online)	1362-4962 ; 1362-4954
ISSN	0301-5610 ; 0305-1048
DOI	10.1093/nar/gkv505
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Volltext online

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1067: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Monitoring RNA unwinding by the transcription termination factor Rho from Mycobacterium tuberculosis.

D'Heygère, François / Schwartz, Annie / Coste, Franck / Castaing, Bertrand / Boudvillain, Marc

Methods in molecular biology (Clifton, N.J.)

2015 Band 1259, Seite(n) 293–311

Abstract: Transcription termination factor Rho is a ring-shaped, homo-hexamieric RNA translocase that dissociates transcription elongation complexes and transcriptional RNA-DNA duplexes (R-loops) in bacteria. The molecular mechanisms underlying these biological ... ...

Abstract	Transcription termination factor Rho is a ring-shaped, homo-hexamieric RNA translocase that dissociates transcription elongation complexes and transcriptional RNA-DNA duplexes (R-loops) in bacteria. The molecular mechanisms underlying these biological functions have been essentially studied with Rho enzymes from Escherichia coli or close Gram-negative relatives. However, phylo-divergent Rho factors may have distinct properties. Here, we describe methods for the preparation and in vitro characterization (ATPase and helicase activities) of the Rho factor from Mycobacterium tuberculosis, a specimen with uncharacteristic molecular and enzymatic features. These methods set the stage for future studies aimed at better defining the diversity of enzymatic properties of Rho across the bacterial kingdom.
Mesh-Begriff(e)	Mycobacterium tuberculosis/metabolism ; RNA/chemistry ; RNA/metabolism ; RNA Helicases/metabolism ; Rho Factor/metabolism ; Viral Nonstructural Proteins/metabolism
Chemische Substanzen	Rho Factor ; Viral Nonstructural Proteins ; RNA (63231-63-0) ; RNA Helicases (EC 3.6.4.13)
Sprache	Englisch
Erscheinungsdatum	2015
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1940-6029
ISSN (online)	1940-6029
DOI	10.1007/978-1-4939-2214-7_18
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: A necrotizing wound after caesarean delivery.

Van Moerkercke, Wouter / D'Heygere, François

Journal of general internal medicine

2010 Band 25, Heft 11, Seite(n) 1242–1243

Mesh-Begriff(e)	Anti-Bacterial Agents/therapeutic use ; Cesarean Section/adverse effects ; Cyclosporine/therapeutic use ; Female ; Gangrene/drug therapy ; Gangrene/etiology ; Gangrene/pathology ; Humans ; Pregnancy ; Wound Healing ; Wounds and Injuries/drug therapy ; Wounds and Injuries/etiology ; Wounds and Injuries/pathology ; Young Adult
Chemische Substanzen	Anti-Bacterial Agents ; Cyclosporine (83HN0GTJ6D)
Sprache	Englisch
Erscheinungsdatum	2010-06-22
Erscheinungsland	United States
Dokumenttyp	Case Reports ; Journal Article
ZDB-ID	639008-0
ISSN	1525-1497 ; 0884-8734
ISSN (online)	1525-1497
ISSN	0884-8734
DOI	10.1007/s11606-010-1429-3
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2205: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.

Bielen, R / Moreno, C / Van Vlierberghe, H / Bourgeois, S / Mulkay, J-P / Vanwolleghem, T / Verlinden, W / Brixco, C / Decaestecker, J / de Galocsy, C / Janssens, F / Van Overbeke, L / Van Steenkiste, C / D'Heygere, F / Cool, M / Wuyckens, K / Nevens, F / Robaeys, G

Journal of viral hepatitis

2017 Band 24, Heft 11, Seite(n) 976–981

Abstract: Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or ... ...

Abstract	Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score ≥ B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015. Patients treated with PEG-IFN+DAA (53±9y) were younger than patients treated with DAA without PEG-IFN (59±12y) (P=.001). 47% of patients treated with PEG-IFN+DAA were in the F4 stage vs 67% of patients treated with DAA without PEG-IFN (P=.001). Screening was inadequate in 20% of both patient groups (P=.664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively (P=.540). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN (P=.857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate.
Sprache	Englisch
Erscheinungsdatum	2017-11
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	1212497-7
ISSN	1365-2893 ; 1352-0504
ISSN (online)	1365-2893
ISSN	1352-0504
DOI	10.1111/jvh.12726
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 4119: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen